For immediate-release veterinary tablet manufacture, orbifloxacin is pre-milled through a cone mill fitted with a 0.8 mm rasp screen before dry blending. A typical tablet core formulation places the API at 2–12% w/w, depending on labelled strength. Microcrystalline cellulose and lactose monohydrate form the major diluent phase, while crospovidone at 3–5% w/w functions as a superdisintegrant. Wet granulation is selected over direct compression when the D90 of the milled API exceeds 180 µm and the blend shows segregation in a 300 L bin blender. The granulation fluid is purified water containing 5% w/w povidone K30 as binder, added at 20–25% w/w of the dry blend. High-shear wet massing is run at a tip speed of 4 m/s for 3–5 minutes, followed by fluid-bed drying at an inlet air temperature of 60 °C until the granule loss on drying is 1.5–2.5% w/w by USP <731>. Drying beyond 0.8% w/w residual moisture leads to brittle granules and increased fines, while residual moisture above 3.0% w/w causes sticking on the punch faces in subsequent compression. The dried granulate is screened through a 1.0 mm oscillating sieve and lubricated with 1% w/w magnesium stearate for 3 minutes in a diffusion mixer.

Compression is performed on a 16-station rotary tablet press equipped with 7 mm round, flat-faced bevelled punches. The precompression force is set at 6–8 kN and the main compression force is held between 12 kN and 18 kN. Tablet hardness is maintained at 60–90 N to achieve disintegration in 0.1 M hydrochloric acid within 15 minutes per USP <701>. Content uniformity is assessed per USP <905>, with an acceptance value not exceeding 15 across 10 dosage units. Dissolution is run per USP <711> using Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid; release limits are derived from the approved regulatory file because published compendial monographs for orbifloxacin tablets are currently limited. The terminal product is a light-protected, film-coated immediate-release tablet for companion animals, packed in aluminium blisters. Coating is applied in a side-vented pan using an aqueous hydroxypropyl methylcellulose system at 38–42 °C bed temperature to protect the API from photodegradation without altering the dissolution profile.

What Limits Sterile Filtration Throughput in Orbifloxacin Parenterals?

Orbifloxacin base exhibits pH-dependent aqueous solubility that is sufficient for a clear injectable solution only when the pH is held below 4.5 or above 9.0. Acidic formulation is preferred because alkaline solutions increase pain on injection and accelerate oxidation. A pilot parenteral at 50 mg/mL orbifloxacin is prepared by adding the API to Water for Injection at 30–35 °C with hydrochloric acid 1 M or methanesulfonic acid 0.5 M to a target pH of 3.8 ± 0.3. The pH adjustment step is run under nitrogen sparging at 2 L/min in a 100 L glass-lined reactor, because orbifloxacin is susceptible to photo-oxidation in the presence of dissolved oxygen. Once the solution is clear, sodium chloride is added to 0.7% w/v for osmolality adjustment, and the batch is cooled to 20–25 °C before filtration. The pH range is narrow: below 3.4, the formulation may exceed the tolerable osmolality after neutralisation, while above 4.6, precipitation can occur during filtration or terminal sterilisation.

Bioburden reduction is performed through a 0.45 µm polyethersulfone cartridge followed by two 0.22 µm PVDF capsule filters in series. Filter capacity is evaluated by constant-pressure 1.0 bar filtration with a 47 mm disc, and the maximum throughput is recorded at the point where flow rate falls to 80% of the initial value. Orbifloxacin at acidic pH can adsorb onto nylon membranes, so PVDF or polyethersulfone membranes are selected; filter compatibility is confirmed by recovery studies and bacterial retention per ASTM F838-20. Terminal sterilisation at 121 °C for 15 minutes is applied to sealed 100 mL amber type II glass vials. The F0 value is recorded above 12 minutes. Post-sterilisation assay and related substances are determined by HPLC, and the total degradation products should remain within the limit set by ICH Q3B for the highest clinical dose if oxygen is excluded and the pH does not drift above 4.4.

Particulate matter testing per USP <788> is required on the finished vials, with no more than 25 particles ≥10 µm and 3 particles ≥25 µm per container. Sterility testing is performed per USP <71> with membrane filtration of 20 containers. The terminal product is a clear, sterile injection for intramuscular or subcutaneous administration in cattle, pigs, or cats where authorised. Filling is conducted under Grade A with Grade B background per EU GMP Annex 1, using a peristaltic line with platinum-cured silicone tubing. The tubing is replaced after every batch to prevent leachable accumulation and spallation defects. Batch-to-batch pH variation above 0.2 units has been observed when the acidulant feed rate is not controlled by in-line pH probe, so pH correction is performed before final filtration rather than after.

For hard gelatin capsule preparations used in veterinary compounding or small-batch pharmaceutical lines, orbifloxacin is pre-dispersed by geometric dilution before encapsulation. The API is jet-milled to a D90 of 75 µm, and a 1:10 pre-blend with lactose monohydrate is mixed in a 5 L V-blender at 25 rpm for 20 minutes. Further dilution to 1:100 with microcrystalline cellulose is performed in the same blender to improve flow before filling. The final fill weight is typically 180–220 mg for size 3 hard gelatin capsules, with orbifloxacin content between 10 mg and 40 mg per capsule. The blend is lubricated with 0.5% w/w magnesium stearate and 0.5% w/w sodium stearyl fumarate for 5 minutes, and then filled on an automatic capsule machine with pin-type dosator. The process is run at 40–50% RH and 20–23 °C to reduce static charge and prevent shell brittleness.

Content uniformity of filled capsules is checked per USP <905>, and dissolution is evaluated using USP <711> Apparatus 1 at 100 rpm in 0.1 M hydrochloric acid. Capsule moisture is controlled to 9–12% w/w by loss on drying per USP <731>, because over-dried gelatin shells fracture during transport and high-moisture shells cross-link with trace aldehyde impurities. Non-sterile oral veterinary drugs are manufactured under 21 CFR 211 when distributed in regulated markets. The terminal product is a hard gelatin capsule intended for oral administration to dogs, cats, or exotic companion species under veterinary prescription. Packaging in amber glass bottles with desiccant canisters is used to limit light and moisture ingress; a 2 g silica gel canister per 60 mL bottle is a typical starting point, with desiccant load adjusted by sorption isotherm data. Published stability data for this specific orbifloxacin capsule configuration is limited, so each distributor should confirm in-house photostability and moisture-barrier studies to the destination market.

When a Soluble Powder Must Resist Caking at 75% RH

Oral water-soluble powders containing orbifloxacin are prepared by dry blending the milled API with citric acid monohydrate and dextrose or lactose. The API loading is usually 5–20% w/w, depending on the labelled concentration after reconstitution in drinking water. Citric acid at 10–20% w/w reduces the local pH of the reconstituted solution to below 4.5, which improves the dissolution of the weakly acidic orbifloxacin base. In a 200 L double-ribbon mixer, the components are blended at 20 rpm for 15 minutes after a stepwise dilution from a 1:5 pre-blend. The final powder is passed through a 500 µm stainless-steel screen and filled into foil sachets at 20–25 °C and 35–40% RH. The low-humidity filling environment is required because the formulation is hygroscopic; caking occurs when the powder is exposed to 75% RH for more than 4 hours, forming hard lumps that do not disperse.

Dissolution performance is tested by adding 1 g of powder to 1 L of water at 20 °C with stirring at 200 rpm; the solution should become visually clear within 5 minutes. The pH of the resulting solution is confirmed to be 3.8–4.5, and assay is determined by HPLC against a reference standard. Moisture content of the powder is controlled by loss on drying per USP <731> to below 1.5% w/w. Water activity is measured by a dew-point instrument and maintained at ≤0.60 aw to prevent hydrolytic degradation and microbial growth. The terminal product is a unit-dose or multi-dose oral soluble powder for addition to drinking water for poultry or swine, where regulatory approval exists. The sachet film is a polyethylene-aluminium-polyethylene laminate with a moisture vapour transmission rate below 0.5 g/m²/day at 38 °C/90% RH, tested according to ASTM F1249-20.

A 15 °C Product-Temperature Window Controls Residual Moisture in Orbifloxacin Granulation

When top-spray fluid-bed granulation is selected for feed-directed orbifloxacin granules, the API loading is kept at 0.5–5% w/w on a carrier of lactose, maize starch, or microcrystalline cellulose. The binder solution is purified water with 3–5% w/w povidone K30 or pregelatinised starch. In a 10 kg batch, the inlet air temperature is set to 55–65 °C, and the product temperature is held between 32 °C and 38 °C. If product temperature exceeds 40 °C, the binder dries before droplet coalescence, producing friable granules with high dust generation. Below 30 °C, the bed defluidises and lumps form. The spray rate is maintained at 40–80 g/min, and atomising air pressure is set to 2.0–2.5 bar to generate a droplet size of 20–40 µm. After spraying, drying continues until the exhaust air relative humidity falls to 10–15% and granule loss on drying reaches 1.5–2.5% w/w per USP <731>.

The dried granules are screened through a 1.0 mm sieve and blended in a 50 L bin blender for 10 minutes. Blend uniformity is evaluated by sampling 10 locations and analysing orbifloxacin by HPLC; the relative standard deviation is typically below 3.0%. Hardness and friability of the granules are controlled because soft granules disintegrate during pneumatic feed conveying, while hard granules resist release in the gastro-intestinal tract. The terminal product is a granule for direct top-dressing on feed at the required therapeutic dose. Packaging in multi-layer paper bags with an inner polyethylene liner is used after residual oxygen is purged with nitrogen; stability under ICH 25 °C/60% RH conditions is monitored for 24 months.

Across the Feed Mill, Orbifloxacin Premix Dilution Requires Staged Sampling

A premix line handling orbifloxacin must be designed as a stepwise dilution train rather than a single-shot blend. The premix may contain the API at 2–10% w/w on a carrier of calcium carbonate, soy hulls, rice hulls, or a mineral-oil-treated silica. The first dilution step is 1:10, followed by 1:10 or 1:20 reductions until the target premix concentration is reached. Mixing is carried out in a horizontal ribbon mixer at 25–35 rpm for 10–15 minutes. A sample thief is used to collect 10 points across the mixer, and the coefficient of variation for orbifloxacin content should not exceed 5.0%. Sampling plans and analytical controls follow ISO 6497:2002 where applicable for feed matrices.

Carryover validation in the feed mill is required because orbifloxacin is a pharmacologically active substance. In the EU, medicated feed must comply with Regulation (EC) No 183/2005 and Regulation (EU) 2019/4; carryover limits and homogeneity requirements are defined in the marketing authorisation. The first feed batch after a non-medicated flush is sampled at the beginning, middle, and end of the discharge line to verify that residual active substance falls below the maximum permitted carryover. No general universal limit applies to all species, so the destination market approval must be consulted before setting the release specification. The terminal product is a medicated premix, often called a Type B medicated feed in US regulatory language, intended for further mixing to complete feed. The premix is packaged in 20 kg multi-wall paper bags with a polyethylene liner, and lot-to-lot tracer studies are performed using ferric oxide or sodium chloride as a visible marker to confirm mixing time.

An oral solution dosage form is prepared when drinking water medication requires a liquid concentrate that can be metered through a proportional dosing pump. Orbifloxacin is dissolved in a co-solvent system of purified water and propylene glycol, with citric acid or hydrochloric acid used to adjust the pH to 3.5–4.5. The final concentration may be 10–50 mg/mL depending on the species and dosing pump calibration. Dissolution is performed in a 50 L stainless-steel mixing vessel at 25–40 °C with moderate agitation for 30–60 minutes. The solution is then cooled to 20 °C and filtered through a 10 µm polypropylene polish filter to remove undissolved raw-material particles. The filtrate is filled into amber PET or type III glass bottles with aluminium-foil induction seals and child-resistant closures. The amber glass or PET with UV barrier limits photodegradation; a headspace purge with nitrogen before capping reduces oxidative degradation.

Stability of the oral solution is evaluated under ICH long-term conditions of 25 °C/60% RH and accelerated conditions of 40 °C/75% RH for 6 months. pH drift, assay, and related substances are monitored by HPLC. A pH above 4.6 may induce precipitation in the bottle, especially at low temperatures of 2–8 °C. Dose uniformity at the point of use is verified by measuring the output of the dosing pump at 100 mL and 1 L calibration points; in field installations, the pump stroke should be checked against volumetric calibration on each farm visit. The terminal product is an oral solution for pigs, poultry, or companion animals, added to drinking water at a rate set by the veterinarian. The solution should be protected from light and used within the in-use stability period after opening; published data for orbifloxacin oral solution in specific species is limited, so in-use study data must be generated for the target market.